Navana Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 1/6
Navana Pharmaceuticals has a total shareholder equity of BDT4.6B and total debt of BDT5.3B, which brings its debt-to-equity ratio to 115.5%. Its total assets and total liabilities are BDT11.3B and BDT6.7B respectively. Navana Pharmaceuticals's EBIT is BDT991.8M making its interest coverage ratio 2.1. It has cash and short-term investments of BDT267.8M.
Key information
115.5%
Debt to equity ratio
৳5.27b
Debt
| Interest coverage ratio | 2.1x |
| Cash | ৳267.77m |
| Equity | ৳4.56b |
| Total liabilities | ৳6.74b |
| Total assets | ৳11.30b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: NAVANAPHAR's short term assets (BDT5.5B) do not cover its short term liabilities (BDT6.3B).
Long Term Liabilities: NAVANAPHAR's short term assets (BDT5.5B) exceed its long term liabilities (BDT447.8M).
Debt to Equity History and Analysis
Debt Level: NAVANAPHAR's net debt to equity ratio (109.6%) is considered high.
Reducing Debt: Insufficient data to determine if NAVANAPHAR's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: NAVANAPHAR's debt is not well covered by operating cash flow (13.4%).
Interest Coverage: NAVANAPHAR's interest payments on its debt are not well covered by EBIT (2.1x coverage).